Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections

To determine neutralizing activity against the severe acute respiratory syndrome coronavirus 2 ancestral strain and 4 variants of concern, we tested serum from 30 persons with breakthrough infection after 2-dose vaccination. Cross-variant neutralizing activity was comparable to that after 3-dose vac...

Full description

Saved in:
Bibliographic Details
Published in:Emerging infectious diseases 2022-05, Vol.28 (5), p.1050-1052
Main Authors: Tober-Lau, Pinkus, Gruell, Henning, Vanshylla, Kanika, Koch, Willi M, Hillus, David, Schommers, Philipp, Suárez, Isabelle, Suttorp, Norbert, Sander, Leif Erik, Klein, Florian, Kurth, Florian
Format: Article
Language:English
Subjects:
2019 novel coronavirus disease
Antibodies, Neutralizing
Antibodies, Viral
coronavirus disease
COVID-19
Cross-Variant Neutralizing Antibodies after SARS-CoV-2 Breakthrough Infections
Drug dosages
Humans
Infections
Infectious diseases
mRNA vaccines
Mutation
Research Letter
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccination
viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine neutralizing activity against the severe acute respiratory syndrome coronavirus 2 ancestral strain and 4 variants of concern, we tested serum from 30 persons with breakthrough infection after 2-dose vaccination. Cross-variant neutralizing activity was comparable to that after 3-dose vaccination. Shorter intervals between vaccination and breakthrough infection correlated with lower neutralizing titers.
ISSN:1080-6040
1080-6059
DOI:10.3201/eid2805.220271